Diet & Weight Loss Archive

Women live longer than men. However, that longevity gap in the United States has increased to 5.8 years, the largest gap since 1996, according to a 2024 study. Why the widening gap? Researchers believe that in many cases, women are better than men at addressing certain health needs that contribute to longer lives, such as losing excess weight, quitting smoking, getting regular skin check-ups, and not ignoring mental health issues.

Obesity is a common, chronic disease that can harm the heart. The powerful weight-loss medications known as GLP-1s, semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), are now recommended as first-line therapy for eligible people, according to the American College of Cardiology. People using these drugs should work with a dietitian or nutritionist who can help them create a personalized eating plan that ensures they’re getting enough nutrients while minimizing common side effects.

Semaglutide, a GLP-1 agonist used to treat diabetes and obesity, may also help people with metabolic dysfunction–associated steatohepatitis, a severe stage of fatty liver disease, suggests a 2025 study.

A 2025 research review found that healthy adults who paired exercise with time-restricted eating lost more fat than participants who didn’t restrict their eating window—without sacrificing lean muscle tissue.

Metabolic syndrome is defined as having at least three of the following: abdominal obesity, high blood triglyceride levels, high blood pressure, high blood sugar levels, and low HDL cholesterol levels. The condition significantly increases the risk for cardiovascular disease, diabetes, kidney disease, fatty liver disease, and sleep apnea. While each factor is problematic, the main driver is abdominal obesity, from visceral fat surrounding internal organs. The best way to reduce visceral fat is aerobic exercise, strength training, and a plant-based diet.

A 2025 study found that a pill version of the drug semaglutide, marketed as Rybelsus, can lower the risk for serious heart problems in people who have diabetes as well as cardiovascular disease, kidney disease, or both.

In a 2025 study, researchers estimated that fewer than four emergency department visits attributed to semaglutide (Ozempic, Wegovy) occurred for every 1,000 patients taking the drug in 2022 and 2023. Most of the visits were related to gastrointestinal problems.

A randomized controlled trial published in 2025 found that people who followed a 4:3 intermittent fasting plan for one year, eating only 20% of their usual calories on three fasting days per week, lost more weight than people who were on a calorie-restricted diet.